Analysts expect Autolus Therapeutics Ltd – (NASDAQ:AUTL) to post ($0.67) earnings per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Autolus Therapeutics’ earnings. The highest EPS estimate is ($0.60) and the lowest is ($0.73). Autolus Therapeutics posted earnings per share of ($0.65) during the same quarter last year, which would indicate a negative year-over-year growth rate of 3.1%. The company is scheduled to announce its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that Autolus Therapeutics will report full-year earnings of ($2.77) per share for the current fiscal year, with EPS estimates ranging from ($2.97) to ($2.40). For the next financial year, analysts forecast that the firm will report earnings of ($3.14) per share, with EPS estimates ranging from ($4.00) to ($2.36). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that cover Autolus Therapeutics.
Autolus Therapeutics (NASDAQ:AUTL) last issued its earnings results on Thursday, May 7th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.14. The company had revenue of $0.34 million during the quarter, compared to analysts’ expectations of $1.15 million. Autolus Therapeutics had a negative return on equity of 45.59% and a negative net margin of 9,870.67%.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in AUTL. Citigroup Inc. raised its position in shares of Autolus Therapeutics by 194.9% in the 4th quarter. Citigroup Inc. now owns 2,041 shares of the company’s stock worth $27,000 after acquiring an additional 1,349 shares in the last quarter. Legal & General Group Plc raised its position in shares of Autolus Therapeutics by 31.5% in the 1st quarter. Legal & General Group Plc now owns 4,623 shares of the company’s stock worth $27,000 after acquiring an additional 1,108 shares in the last quarter. Tower Research Capital LLC TRC bought a new position in shares of Autolus Therapeutics in the 4th quarter worth approximately $29,000. Advisor Group Holdings Inc. bought a new position in shares of Autolus Therapeutics in the 1st quarter worth approximately $46,000. Finally, Burrage Capital Management LLC raised its position in shares of Autolus Therapeutics by 14.4% in the 1st quarter. Burrage Capital Management LLC now owns 15,006 shares of the company’s stock worth $84,000 after acquiring an additional 1,893 shares in the last quarter. 38.12% of the stock is owned by institutional investors and hedge funds.
AUTL stock traded down $0.07 during trading on Monday, hitting $12.92. 480,651 shares of the company traded hands, compared to its average volume of 154,372. Autolus Therapeutics has a 1 year low of $3.00 and a 1 year high of $19.34. The company has a 50-day moving average of $11.10 and a 200-day moving average of $10.52. The company has a current ratio of 10.78, a quick ratio of 10.78 and a debt-to-equity ratio of 0.08.
About Autolus Therapeutics
Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma.
Further Reading: Stop Order Uses For Individual Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.